Cadila Healthcare share price increases after receiving the approval for ZyCoV-D, the first Plasmid DNA vaccine in the world for coronavirus to be distributed needle-free to teenagers.
Several vaccines have been developed so far for the adult population. Cadila Healthcare, an Indian pharmaceutical company, created the world’s first Plasmid DNA vaccine for coronavirus for teenagers. If you want to be one of the first investors in this high-potential company, keep reading.
The next sections introduce you to the first needle-free vaccine in the world for COVID-19, why you should buy Cadila Healthcare and a curated list of the top online brokers to buy Cadila Healthcare stock.
How & Where to Buy Cadila Healthcare Stock Online
If you want to buy Cadila Healthcare (NSE: CADILAHC), you have several options. All you need to do is choose and register with one of the brokers below and deposit your capital to start trading Cadila Healthcare stock right now.
eToro is one of the world's leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It's social copy trading features make it a great choice for those getting started.
Financial company driven by technology and offering all-in-one self-directed investment platform that provides excellent user experience.
What Is Cadila Healthcare?
Cadila Healthcare is an Indian multinational pharmaceutical company that manufactures generic drugs. The company has recently received the Emergency Use Authorisation from India’s controlling authority for its new vaccine, ZyCoV-D. This is the first Plasmid DNA Vaccine developed for coronavirus, and it is to be distributed to children between 12 and 18 years old.
The company plans to start administering the vaccine in September and it has three doses. The vaccine is a needle-free innovation administered via PharmaJet, which delivers intramuscular or subcutaneous medication without needles.
Should I Buy Cadila Healthcare Today?
The ZyCoV-D is the first vaccine of this type – to be approved on a DNA platform – and the sixth COVID-19 vaccine in India. As a result, investors and traders alike might consider this stock a profitable opportunity – first, because of its subsequent surge in share price that might pick up during today’s trading session. Also, there is a meaningful opportunity for long-term returns as the adoption of this vaccine increases in the next months.
Cadila Healthcare Price Prediction 2021
Most analysts upgraded their rating to buy with the highest share price prediction of RS 664 by Morgan Stanley. Also, CLSA has a price target of RS 650 and expects the stock to report a double-digit core growth in FY2023.